Claims

1. A composition comprising
   a) 2-methyl-1-(2-(5-(*p*-tolyl)-1*H*-imidazol-2-yl)piperidin-1-yl)butan-1-one,
   b) and a solvent selected from the group consisting of 2-phenylethanol, phenoxyethyl alcohol, and mixtures thereof.

2. The composition according to claim 1, wherein 2-methyl-1-(2-(5-(*p*-tolyl)-1*H*-imidazol-2-yl)piperidin-1-yl)butan-1-one as is present in at least 1 % or more by weight of the total composition, or in at least 5 % or more by weight of the total composition, or in at least 10 % or more by weight of the total composition, or in at least 15 % or more by weight of the total composition, or in at least 20 % or more by weight of the total composition, or in at least 25 % or more by weight of the total composition.

3. The composition according to any one of the previous claims, wherein the weight ratio of 2-methyl-1-(2-(5-(*p*-tolyl)-1*H*-imidazol-2-yl)piperidin-1-yl)butan-1-one as (a) to solvent (b) is 1:3 to 1:99.

4. The composition according to any one of the previous claims, comprising, consisting essentially of, or consisting of (a) 1 – 25 % by weight of 2-methyl-1-(2-(5-(*p*-tolyl)-1*H*-imidazol-2-yl)piperidin-1-yl)butan-1-one as according to formula (I), and (b) 75 – 99 % by weight of the solvent selected from the group consisting of 2-phenylethanol, phenoxyethyl alcohol, and mixtures thereof, related to weight of the total composition, provided that (a) and (b) add up to 100 weight %.

5. A use of the composition according to any one of the previous claims in fragrance formulations.

6. A fragrance formulation comprising the composition as defined in any one of claims 1 to 3, further comprising at least one fragrance compound.

7. The fragrance formulation according to claim 6, further comprising a further cooling compound selected from 2-(4-ethylphenoxy)-*N*-(1H-pyrazol-3-yl)-*N*-(thiophen-2-ylmethyl)acetamide, 2-isopropyl-5-methyl-*N*-(2-(pyridin-2-yl)ethyl)cyclohexane-1-carboxamide (including (1*R*,2*S*,5*R*)-2-isopropyl-5-methyl-*N*-(2-(pyridin-2-yl)ethyl)cyclohexane-1-carboxamide), *N*-(4-(cyanomethyl)phenyl)-2-isopropyl-5-

methylcyclohexane-carboxamide (including (1*R*,2*S*,5*R*)-*N*-(4-(cyanomethyl)phenyl)-2-isopropyl-5-methylcyclohexane-carboxamide), *N*-Ethyl-*p*-menthane-3-carboxamide, ethyl (2-isopropyl-5-methylcyclohexane-1-carbonyl)glycinate, 2-isopropyl-*N*,2,3-trimethylbutanamide, *N*-(4-(2-amino-2-oxoethyl)phenyl)-2-isopropyl-5-methylcyclohexane-1-carboxamide (including rac-(1*R*,2*S*,5*R*)-*N*-(4-(2-amino-2-oxoethyl)phenyl)-2-isopropyl-5-methylcyclohexane-1-carboxamide), 2-isopropyl-5-methylcyclohexyl 2-hydroxypropanoate, *N*-(2-hydroxy-2-phenylethyl)-2-isopropyl-5,5-dimethylcyclohexane-1-carboxamide.

8. A fragranced product, comprising a product base and the composition according to any one of claims 1 to 4, or the fragrance formulation according to claim 6 or 7.

9. The fragranced product according to claim 8, wherein the composition is comprised in a cooling effect-providing proportion.

10. A method of incorporating 2-methyl-1-(2-(5-(*p*-tolyl)-1*H*-imidazol-2-yl)piperidin-1-yl)butan-1-one as compound in a fragranced product, comprising

a) the blending of 2-methyl-1-(2-(5-(*p*-tolyl)-1*H*-imidazol-2-yl)piperidin-1-yl)butan-1-one as, or a salt or solvate thereof, with a solvent selected from the group consisting of 2-phenylethanol, phenoxyethyl alcohol, and mixtures thereof, and

b) the addition of the resulting composition to the fragranced product.

11. A method of providing a cooling sensation for the skin to a fragranced product, comprising the addition of a cooling effect-providing proportion of a composition according to any one of claims 1 to 4 to a product base.

12. A crystalline form of 2-methyl-1-(2-(5-(p-tolyl)-1H-imidazol-2-yl)piperidin-1-yl)butan-1-one characterized by main peaks in its powder X-ray diffraction pattern obtained using copper K-alpha, radiation at 2-theta angles of 9.53, 11.61, 12.90, 14.28, 14.51, 17.10, 19.15, 19.41, 19.56, 19.88, 20.70, 21.03, 22.61, 27.07 and 28.81 degrees.

13. A method of making a solution of the crystalline form of 2-methyl-1-(2-(5-(p-tolyl)-1H-imidazol-2-yl)piperidin-1-yl)butan-1-one according to claim 14, comprising the step of solubilizing the crystalline form of 2-methyl-1-(2-(5-(p-tolyl)-1H-imidazol-2-yl)piperidin-

1-yl)butan-1-one in a solvent selected from the group consisting of 2-phenylethanol, phenoxyethyl alcohol, and mixtures thereof.